High-Fidelity Long-Read Sequencing Market Report 2026

The high-fidelity long-read sequencing market size has grown exponentially in recent years. It will grow from $1.53 billion in 2025 to $1.88 billion in 2026 at a compound annual growth rate (CAGR) of 22.2%. The growth in the historic period can be attributed to advancements in sequencing chemistry accuracy, early adoption in genomics research institutions, expansion of large-scale genome projects, increasing demand for structural variant analysis, improvements in sequencing hardware performance.

The high-fidelity long-read sequencing market size is expected to see exponential growth in the next few years. It will grow to $4.22 billion in 2030 at a compound annual growth rate (CAGR) of 22.5%. The growth in the forecast period can be attributed to growing use of precision medicine approaches, rising investments in genomics-based drug discovery, expansion of rare disease research, increasing clinical adoption of long-read sequencing, advancements in sequencing cost efficiency. Major trends in the forecast period include increasing adoption of long-read sequencing in clinical diagnostics, rising demand for high-accuracy variant detection, growing use of de novo genome assembly techniques, expansion of epigenetic and transcriptomic analysis applications, enhanced integration of advanced bioinformatics tools.

The rising occurrence of rare diseases is expected to accelerate the growth of the HiFi long-read sequencing market in the foreseeable future. Rare diseases are conditions that affect a small population, typically with complex symptoms and limited treatment options. The prevalence of rare diseases is increasing due to improvements in genetic sequencing and diagnostic tools, which enable earlier and more precise detection of previously unrecognized or misdiagnosed conditions. HiFi long-read sequencing contributes to the management of rare diseases by providing highly accurate and comprehensive identification of complex genetic variants often missed by short-read sequencing, resulting in faster and more precise diagnoses. For example, in July 2023, the Department of Health & Social Care, a UK government entity, estimated that over 7,000 rare diseases exist, with new conditions continually being identified through ongoing research. Approximately 80% of these rare diseases have a genetic origin. Consequently, the rising prevalence of rare diseases is propelling the growth of the HiFi long-read sequencing market.

Key companies operating in the HiFi long-read sequencing market are focusing on developing innovative solutions, such as hybrid-capture target enrichment, to enhance sequencing accuracy, increase coverage of complex genomic regions, and accelerate the detection of structural variants for advanced research and clinical applications. Hybrid-capture target enrichment refers to a genomic sequencing technique that selectively isolates specific regions of DNA or RNA from a sample using complementary probes, allowing for focused, high-accuracy sequencing of target regions while reducing sequencing of non-relevant regions. For example, in July 2025, QIAGEN N.V., a Netherlands-based biotechnology company, launched QIAseq xHYB Long Read Panels to expand its next-generation sequencing (NGS) offerings. It uses hybrid-capture enrichment to enable precise long-read sequencing of complex genomic regions like repeats and structural variants, overcoming short-read limitations. They offer superior uniformity, specificity, and complete coverage for applications in cancer profiling, HLA typing, and haplotype phasing, with flexible fixed or custom formats and integrated workflows from DNA prep to bioinformatics analysis. Benefits include streamlined efficiency and deeper insights for precision medicine.

In November 2025, Agilent Technologies Inc., a US-based life sciences firm, collaborated with Pacific Biosciences of California Inc. to improve genomic sequencing solutions and accelerate research applications. This collaboration aims to drive the adoption of PacBio's HiFi long-read sequencing in clinical diagnostic testing by integrating Agilent's target enrichment panels for effective detection of complex genomic variants, thereby enhancing diagnostic yield and increasing global laboratory access. Pacific Biosciences of California Inc. is a US-based company providing HiFi long-read sequencing technologies for precise genomic analysis and research applications.

Major companies operating in the high-fidelity long-read sequencing market are Azenta Inc., BGI Genomics Co. Ltd., GenScript Biotech Corporation, Novogene Co. Ltd., Takara Bio Inc., Pacific Biosciences of California Inc., Macrogen Inc., MedGenome Inc., MGI Tech Co. Ltd., Discovery Life Sciences Inc., Eurofins Genomics LLC, CD Genomics, BaseClear B.V., Psomagen Inc., Health in Code S.L., Creative Biogene Inc., Nucleome Informatics Private Limited, Genevia Technologies Oy, JS Link Co. Ltd., SeqCenter LLC, Theragen Bio Co. Ltd.

Tariffs are influencing the high-fidelity long-read sequencing market by increasing costs of imported sequencing instruments, flow cells, reagents, microfluidic components, and high-performance computing hardware. Research institutions and clinical laboratories in North America and Europe are most affected due to reliance on specialized imported equipment, while Asia-Pacific faces cost pressure on sequencing platform manufacturing and exports. These tariffs are increasing service pricing and slowing infrastructure expansion. However, they are also driving regional production of consumables, local assembly of sequencing instruments, and increased investment in domestic genomics technology ecosystems.

The high-fidelity long-read sequencing market research report is one of a series of new reports that provides high-fidelity long-read sequencing market statistics, including high-fidelity long-read sequencing industry global market size, regional shares, competitors with a high-fidelity long-read sequencing market share, detailed high-fidelity long-read sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the high-fidelity long-read sequencing industry. This high-fidelity long-read sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

High-fidelity long-read sequencing is an advanced DNA sequencing technology that generates long, highly accurate nucleotide reads by repeatedly sequencing single DNA molecules to produce consensus sequences. It combines the benefits of long-read length with low error rates, enabling precise detection of genetic variants, structural rearrangements, and complex genomic regions. It helps to achieve high-resolution, accurate genome analysis for research, diagnostics, and precision medicine.

The primary product types of high-fidelity (HiFi) long-read sequencing include instruments, consumables, and software. Instruments are sequencing systems developed to produce highly accurate long-read DNA or RNA data for sophisticated genomic analysis. These products leverage sequencing technologies such as single-molecule real-time sequencing (SMRT), nanopore sequencing, and other sequencing methods. They are utilized across application areas including clinical diagnostics, genomics research, oncology, rare disease identification, agriculture and animal research, and other applications, and are adopted by end users such as academic and research institutions, hospitals and clinics, pharmaceutical and biotechnology companies, and other end users.

The high-fidelity long-read sequencing market consists of revenues earned by entities by providing services such as sample preparation and library construction, de novo genome assembly, variant detection and phasing, and epigenetic and transcriptomic analysis. The market value includes the value of related goods sold by the service provider or included within the service offering. The high-fidelity long-read sequencing market also includes sales of sequencing consumables and reagents, sample preparation and library construction kits, flow cells and chips, quality control materials, and associated sequencing hardware and software products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.